About this trial
The Phase 2 study has now closed to accrual.
The Phase 3 portion of the study compares the efficacy of Adagrasib in combination with pembrolizumab versus pembrolizumab plus chemotherapy in patients with unresectable, locally advanced or metastatic nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS
Patient Profile
Histologically confirmed diagnosis of unresectable or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS >=50%
Where’s this trial being run?
Beaumont Hospital, St James’s Hospital, Tallaght University Hospital, University Hospital Galway, and University Hospital Waterford
Can I join this study / trial?
The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.
It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.
For more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | Krystal-7 |
|---|---|
| Number: | 22-07 |
| Full Title: | A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation |
| Principal Investigator: | Dr Jarushka Naidoo |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | Mirati Therapeutics |
| Recruitment Started: |
Global: Yes Ireland: Re-opened July 2024 |
| Global Recruitment Target: | 806 |
|---|---|
| Ireland Recruitment Target: | 4 |